May 16 (SeeNews) - Slovenian pharmaceutical products wholesaler Salus [LJE:SALR] said its consolidated net profit declined to 2.8 million euro ($3.1 million) in the first quarter of 2023 from 4.1 million euro in the same period of last year.
Consolidated net sales revenue went up by an annual 12.1% to 140.9 million euro in the three-month period through March 2023, Salus said in a filing with the Ljubljana Stock Exchange on Thursday.
The group's operating profit decreased to 13.6 million euro from 14.7 million euro in January-March 2022, while EBITDA totalled 4.7 million euro, down from 6.3 million euro in the like period of last year.
Ljubljana-based Salus is one of Slovenia's leading wholesalers of pharmaceutical and medical products.
($ = 0.9176 euro)